JP2022514152A5 - - Google Patents
Info
- Publication number
- JP2022514152A5 JP2022514152A5 JP2021518888A JP2021518888A JP2022514152A5 JP 2022514152 A5 JP2022514152 A5 JP 2022514152A5 JP 2021518888 A JP2021518888 A JP 2021518888A JP 2021518888 A JP2021518888 A JP 2021518888A JP 2022514152 A5 JP2022514152 A5 JP 2022514152A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- item
- day
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024114026A JP2024133735A (ja) | 2018-10-04 | 2024-07-17 | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741270P | 2018-10-04 | 2018-10-04 | |
| US62/741,270 | 2018-10-04 | ||
| US201962853904P | 2019-05-29 | 2019-05-29 | |
| US62/853,904 | 2019-05-29 | ||
| US201962894559P | 2019-08-30 | 2019-08-30 | |
| US62/894,559 | 2019-08-30 | ||
| PCT/US2019/054559 WO2020072814A1 (en) | 2018-10-04 | 2019-10-03 | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024114026A Division JP2024133735A (ja) | 2018-10-04 | 2024-07-17 | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514152A JP2022514152A (ja) | 2022-02-10 |
| JP2022514152A5 true JP2022514152A5 (https=) | 2022-10-06 |
| JP7524167B2 JP7524167B2 (ja) | 2024-07-29 |
Family
ID=68318947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518888A Active JP7524167B2 (ja) | 2018-10-04 | 2019-10-03 | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
| JP2024114026A Pending JP2024133735A (ja) | 2018-10-04 | 2024-07-17 | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024114026A Pending JP2024133735A (ja) | 2018-10-04 | 2024-07-17 | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11207299B2 (https=) |
| EP (1) | EP3860594B1 (https=) |
| JP (2) | JP7524167B2 (https=) |
| KR (1) | KR102902972B1 (https=) |
| CN (1) | CN113286587A (https=) |
| AU (1) | AU2019354784B2 (https=) |
| BR (1) | BR112021006132A2 (https=) |
| CA (1) | CA3114434A1 (https=) |
| ES (1) | ES3057657T3 (https=) |
| IL (1) | IL281965B1 (https=) |
| MA (1) | MA53817A (https=) |
| MX (1) | MX2021003606A (https=) |
| WO (1) | WO2020072814A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017985A (zh) | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| WO2022246200A1 (en) * | 2021-05-21 | 2022-11-24 | Travere Therapeutics, Inc. | Methods of treating kidney diseases or disorders |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| HUP0104634A3 (en) | 1998-07-06 | 2002-11-28 | Bristol Myers Squibb Co | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| ATE339417T1 (de) | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| US9719981B2 (en) | 2012-08-17 | 2017-08-01 | Father Flanagan's Boys' Home | RAC1 inhibitors for the treatment of alport glomerular disease |
| CA2958585C (en) * | 2014-08-21 | 2024-01-09 | Stealth Biotherapeutics Corp | Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome |
| EP3515501A1 (en) * | 2016-09-19 | 2019-07-31 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
| CN117017985A (zh) * | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| US20220048900A1 (en) | 2018-12-21 | 2022-02-17 | Travere Therapuetics, Inc. | Amorphous sparsentan compositions |
-
2019
- 2019-10-03 MA MA053817A patent/MA53817A/fr unknown
- 2019-10-03 BR BR112021006132-0A patent/BR112021006132A2/pt unknown
- 2019-10-03 EP EP19791401.3A patent/EP3860594B1/en active Active
- 2019-10-03 IL IL281965A patent/IL281965B1/en unknown
- 2019-10-03 JP JP2021518888A patent/JP7524167B2/ja active Active
- 2019-10-03 MX MX2021003606A patent/MX2021003606A/es unknown
- 2019-10-03 WO PCT/US2019/054559 patent/WO2020072814A1/en not_active Ceased
- 2019-10-03 AU AU2019354784A patent/AU2019354784B2/en active Active
- 2019-10-03 US US16/592,633 patent/US11207299B2/en active Active
- 2019-10-03 CN CN201980079773.4A patent/CN113286587A/zh active Pending
- 2019-10-03 KR KR1020217010358A patent/KR102902972B1/ko active Active
- 2019-10-03 ES ES19791401T patent/ES3057657T3/es active Active
- 2019-10-03 CA CA3114434A patent/CA3114434A1/en active Pending
-
2024
- 2024-07-17 JP JP2024114026A patent/JP2024133735A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514152A5 (https=) | ||
| JP6795571B2 (ja) | グリブリドおよび他の薬剤の静脈内投与方法 | |
| Morse et al. | The treatment of sarcoidosis with chloroquine | |
| CN100335046C (zh) | 组合物 | |
| EA022040B1 (ru) | Применение бетанехола для лечения ксеростомии | |
| JP3221880B2 (ja) | 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用 | |
| US20210386858A1 (en) | Mucoadhesive compositions and uses thereof | |
| JP2004518653A (ja) | 不安障害を治療する方法 | |
| JP2010518171A (ja) | 非冠微小血管疾患の処置のためのラノラジンの使用 | |
| JP2021520400A (ja) | エダラボン医薬組成物 | |
| TW202200142A (zh) | 阿立哌唑注射用製劑之投予方法 | |
| JP2002505280A (ja) | 一過性熱感を軽減するための塩酸フルオキセチン | |
| JPS59181224A (ja) | 安定なインタ−フエロン製剤の製法 | |
| JPH01503146A (ja) | 身体組織の治療方法および身体組織への医薬の投与方法 | |
| JP2021152002A5 (https=) | ||
| JP2021503448A5 (https=) | ||
| JPH0473413B2 (https=) | ||
| JP2002502863A (ja) | 炭酸脱水酵素抑制剤を用いた脳浮腫の治療 | |
| JP2002308764A (ja) | 眼科用医薬組成物 | |
| Berglund et al. | A within‐patient comparison of alprenolol and propranolol in hypertension | |
| JP5172678B2 (ja) | 安定化および保存化したケトチフェン含有眼用組成物 | |
| WO1996004917A1 (en) | Remedy for myotonic dystrophy | |
| JP2024529777A (ja) | ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用 | |
| Jain et al. | Effect of dexmedetomidine on emergence agitation using desflurane in pediatric cataract surgery | |
| Franco et al. | Oral management of Steinert's disease and role of anxiolysis |